SEC Form 4 · accession 0001209191-15-047221
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Tambi
Director
Period of report
May 26, 2015
Accepted (ET)
May 27, 2015 · 6:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 26, 2015 | M | 1,800 | $1.22 | A | 1,800 | D | |
| Common Stock | May 26, 2015 | S | 1,800 | $60.00 | D | 0 | D | |
| Common Stock | May 27, 2015 | M | 3,100 | $1.22 | A | 3,100 | D | |
| Common StockF1 | May 27, 2015 | S | 3,100 | $60.09 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.22 | May 26, 2015 | M | 1,800 | D | — | Feb 21, 2020 | Common Stock | 1,800 | 19,927 | D |
| Stock Option (right to buy)F2 | $1.22 | May 27, 2015 | M | 3,100 | D | — | Feb 21, 2020 | Common Stock | 3,100 | 16,827 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The option is fully vested and exercisable.